Amgen has formally disagreed with the FDA's proposal to withdraw TAVNEOS from the U.S. market, submitting data and analyses to request a hearing. This indicates a potential regulatory battle over the drug's continued availability, which could impact Amgen's revenue stream from TAVNEOS.
Amgen has publicly stated its disagreement with the FDA's proposal to withdraw TAVNEOS (avacopan) from the U.S. market. The company has submitted comprehensive data and analyses to the FDA, formally requesting a hearing to present its case for the drug's continued availability. This development is significant because TAVNEOS is an approved treatment for ANCA-associated vasculitis, and its potential withdrawal could impact patients and Amgen's revenue. For traders, this creates short-term uncertainty around AMGN stock due to the regulatory overhang, with long-term implications depending on the outcome of the FDA hearing. The key risk is the loss of TAVNEOS sales, while the opportunity lies in a successful defense of the drug's market presence.